[1]董文敏,秦旭辉,任伊宁,等.固本抗癌方治疗乳腺癌术后化疗患者骨髓抑制临床疗效[J].陕西中医,2025,46(4):486-489.[doi:DOI:10.3969/j.issn.1000-7369.2025.04.011]
　DONG Wenmin,QIN Xuhui,REN Yining,et al.Clinical effect of Guben Kang'ai prescription on myelosuppression in patients with breast cancer after chemotherapy[J].,2025,46(4):486-489.[doi:DOI:10.3969/j.issn.1000-7369.2025.04.011]
点击复制

固本抗癌方治疗乳腺癌术后化疗患者骨髓抑制临床疗效
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
46
期数:
2025年4期
页码:
486-489
栏目:
临床研究
出版日期:
2025-04-20

文章信息/Info

Title:
Clinical effect of Guben Kang'ai prescription on myelosuppression in patients with breast cancer after chemotherapy
作者:
董文敏1; 秦旭辉2; 任伊宁1; 冯 浩1; 徐 曌1; 兴 伟1
(1.河北中医药大学第一附属医院外一科,河北 石家庄 050011; 2.赞皇县中医院外二科,河北 石家庄 051230)
Author(s):
DONG Wenmin1; QIN Xuhui2; REN Yining1; FENG Hao1; XU Zhao1; XING Wei1
(1.Department of External Medicine,First Affiliated Hospital of Hebei University of Traditional Chinese Medicine,Shijiazhuang 050011,China; 2.Department 2 of External Medicine,Zanhuang County Traditional Chinese Medicine Hospital,Shijiazhuang 051230,China)
关键词:
乳腺癌;  固本抗癌方;  辅助化疗;  骨髓抑制;  免疫功能;  生活质量
Keywords:
Breast cancer;  Guben Kang'ai prescription;  Adjuvant chemotherapy;  Myelosuppression;  Immune function;  Quality of life
分类号:
R 737.9
DOI:
DOI:10.3969/j.issn.1000-7369.2025.04.011
文献标志码:
A
摘要:
目的:观察固本抗癌方对乳腺癌术后化疗患者骨髓抑制的疗效。方法:选择80例乳腺癌术后化疗患者为研究对象,随机分为对照组及观察组各40例,对照组行常规治疗,观察组加用固本抗癌方口服,观察两组骨髓抑制情况。结果:治疗4、8周,观察组中医证候积分显著低于对照组(均P<0.05); 观察组白细胞、血小板、血红蛋白水平显著高于对照组(均P<0.05); 观察组发生Ⅲ度以上骨髓抑制显著低于对照组(均P<0.05); 观察组粒细胞集落刺激因子(GCS-F)用量、血常规恢复正常所需时间显著低于对照组(均P<0.05); 观察组生活质量评分(QOL)、卡氏评分(KPS)显著高于对照组(均P<0.05)。结论:固本抗癌方治疗乳腺癌术后化疗患者,能显著减轻临床症状,提高患者生活质量,改善血细胞异常情况,减轻骨髓抑制,减少GCS-F用量,促进血常规恢复正常。
Abstract:
Objective:To observe the effect of Guben Kang'ai prescription on myelosuppression of postoperative chemotherapy for breast cancer.Methods:A total of 80 cases of postoperative chemotherapy for breast cancer were selected as research subjects,all the enrolled pathologies were randomly divided into 40 cases each in the control and observation groups according to the random number table method,the control group was treated routinely,and the observation group was orally administered with Guben Kang'ai prescription,and the bone marrow suppression of the two groups was observed.Results:After 4 and 8 weeks of treatment,TCM syndrome scores in the observation group were significantly lower than those in the control group(all P<0.05).The levels of leukocyte,platelet and hemoglobin in observation group were significantly higher than those in control group(all P<0.05).After treatment,the incidence of myelosuppression above Ⅲ degree in observation group was significantly lower than that in control group(all P<0.05).The dosage of granulocyte colony-stimulating factor(GCS-F)and the time required for normal blood routine in observation group were significantly lower than those in control group(all P<0.05).After treatment,the quality of life score(QOL)and KPS score in the observation group were significantly higher than those in the control group(all P<0.05).Conclusion:In the treatment of patients with breast cancer after chemotherapy,Guben Kang'ai prescription can significantly reduce clinical symptoms,improve the quality of life of patients,improve blood cell abnormalities,reduce bone marrow suppression,reduce the amount of GCS-F,and promote the normal blood routine.

参考文献/References:

[1] 何思怡,李贺,曹毛毛,等.全球及我国女性乳腺癌疾病负担年龄分布及变化趋势[J].中国肿瘤,2023,32(1):1-7.
[2] 徐婷婷,杨雪玲,李净净.全球女性乳腺癌疾病负担现状分析[J].中国肿瘤,2024,33(7):550-556.
[3] 张蒙,崔永春,王春平,等.1990—2019年中国女性乳腺癌疾病负担及其危险因素变化趋势分析[J].中华肿瘤防治杂志,2022,29(7):456-462.
[4] 刘岩松,张丽莎,马菲,等.浅谈乳腺癌手术中腋窝淋巴结的处理[J].中华外科杂志,2024,62(8):731-736.
[5] 高宇,陈海玲,王心悦,等.乳腺癌新辅助化疗联合免疫治疗的临床研究进展[J].癌症进展,2023,21(23):2560-2564,2587.
[6] 许益琳,宋娜,王晓翠,等.乳腺癌患者化疗中并发症的临床护理[J].实用临床医药杂志,2019,23(7):113-115,120.
[7] 孙琦,李文倩,解友邦,等.化疗后骨髓抑制机制的研究进展[J].国际肿瘤学杂志,2023,50(1):33-36.
[8] CHUDASAMA R,FENTON A M,DIZON S D.Guidelines of Chinese Society of Clinical Oncology(CSCO)on diagnosis and treatment of breast cancer:An appraisal[J].Chin J Cancer Res,2020,1(11):125-131.
[9] 史悦,季汉超.987例化疗药物相关骨髓抑制药品不良反应报告分析[J].中国处方药,2024,22(5):99-102.
[10] 魏小平,谭丽,郑贵星.粒细胞集落刺激因子对骨髓造血细胞及外周血细胞的影响[J].检验医学与临床,2013,10(11):1393-1394.
[11] 单瑞睿.重组人粒细胞集落刺激因子不良反应的文献分析[J].临床合理用药杂志,2022,15(16):165-168.
[12] 朱荟萃,杨静.抗肿瘤药物引起骨髓抑制的中西医治疗研究进展[J].中西医结合研究,2024,16(4):245-249,254.
[13] 张曦,黄瑞昊.细胞治疗与造血干细胞移植新模式的探索与实践[J].中华血液学杂志,2024,45(2):105-108.
[14] 胥瑞婷,马音,朱炜炜.中药提取物榄香烯抗肿瘤临床应用现况[J].陕西中医,2021,42(9):1317-1320.
[15] 赵新月,王桂彬,司徒红林,等.林毅病-证-症结合辨治巩固期乳腺癌经验[J].中医杂志,2024,65(1):26-30.
[16] 张琳,冯正权.冯正权运用和、消、补三法治疗乳腺癌经验介绍[J].新中医,2023,55(18):135-138.
[17] 张美英,张英,侯炜.基于数据挖掘探讨黄芪抗肿瘤复方的临床应用[J].陕西中医,2023,44(7):957-960.
[18] 徐世一,刘秀波,陆佳欣,等.黄芪活性成分抗肿瘤作用机制的研究进展[J].中草药,2022,53(23):7613-7623.
[19] 李静,何牟,李玲,等.白术挥发油化学成分及药理作用研究进展[J].中成药,2024,46(3):881-889.
[20] 王倩.白术内酯抗恶性肿瘤研究进展[J].医学理论与实践,2023,36(5):753-755.
[21] 刘丝雨,刘洁,程博,等.茯苓多糖及三萜类成分抗肿瘤的研究进展[J].中国实验方剂学杂志,2023,29(5):257-263.
[22] 刘哲君,万诗雨.龙葵不同药用部位及药效成分的抗肿瘤机理研究进展[J].时珍国医国药,2023,34(10):2479-2482.
[23] 李香香,王振,杨星,等.半枝莲抗肿瘤的信号通路研究进展[J].中华中医药学刊,2024,42(4):248-253.
[24] 李慧,李军,徐瑞.白花蛇舌草抗肿瘤作用机制的研究进展[J].现代药物与临床,2024,39(7):1921-1926.
[25] 黄岚,陈碧莲,罗镭.白花蛇舌草的化学成分、药理作用及临床应用研究进展[J].中国药事,2023,37(12):1451-1460.

相似文献/References:

[1]陈 楠,王光辉△,贺 赛,等.养正合剂改善乳腺癌术后化疗者不适及对患者细胞因子、红细胞免疫的影响[J].陕西中医,2019,(10):1357.
　CHEN Nan,WANG Guanghui,HE Sai,et al.Yangzheng mixture improves the discomfort of postoperative chemotherapy in patients with breast cancer and its immunity to cytokines and red blood cells[J].,2019,(4):1357.
[2]张贺,姜大庆.鸦胆子素D对乳腺癌MDAMB231细胞增殖与凋亡及细胞周期的影响*[J].陕西中医,2019,(11):1495.
　ZHANG He,JIANG Daqing..Effects of Bruceine D on proliferation,apoptosis and cell cycle of breast cancer MDAMB231 cells[J].,2019,(4):1495.
[3]张栓宝,张燕平△,严宁娟.康莱特注射液对乳腺癌新辅助化疗患者免疫功能、血管内皮生长因子及生活质量的影响[J].陕西中医,2019,(11):1566.
　ZHANG Shuanbao,ZHANG Yanping,YAN Ningjuan..Effect of Kanglaite injection on immune function,VEGF and quality of life in patients with breast cancer receiving neoadjuvant chemotherapy[J].,2019,(4):1566.
[4]贺晓立,王 军,余 静,等.沈力教授治疗乳腺癌十一法*[J].陕西中医,2020,(1):92.
　HE Xiaoli,WANG Jun,YU Jing,et al.Professor SHEN Li’s treatment of breast cancer by using eleven TCM methods[J].,2020,(4):92.
[5]刘歆春,李锁南,黄飞燕.乳岩汤联合西药治疗乳腺癌疗效及对患者免疫功能的影响[J].陕西中医,2021,(9):1201.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.012]
[6]冯秀梅,马 兰,罗玉群,等.益气活血方对乳腺癌MCF-7细胞系增殖侵袭能力及miR-100表达水平影响的研究[J].陕西中医,2021,(11):1527.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.007]
　FENG Xiumei,MA Lan,LUO Yuqun,et al.Yiqi Huoxue recipe to inhibit breast cancer cell proliferation and invasion and increase the expression of miR-100[J].,2021,(4):1527.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.007]
[7]陈 军,孙 嫘,惠建荣,等.艾灸对三阴性乳腺癌移植瘤小鼠生存期的影响及机制研究[J].陕西中医,2022,(7):819.[doi:DOI:10.3969/j.issn.1000-7369.2022.07.001]
　CHEN Jun,SUN Lei,HUI Jianrong,et al.Effect and mechanism of moxibustion on survival of triple negative breast cancer transplanted tumor mice[J].,2022,(4):819.[doi:DOI:10.3969/j.issn.1000-7369.2022.07.001]
[8]陈明明,郭 旭,熊乙霓,等.培元固本法治疗乳腺癌化疗后骨髓抑制临床研究[J].陕西中医,2022,(8):1049.[doi:DOI:10.3969/j.issn.1000-7369.2022.08.014]
[9]蔡丽珍,白瑞娜,张 路,等.基于“痰夹瘀血”理论探讨乳腺癌相关淋巴水肿因机治疗[J].陕西中医,2023,(10):1420.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.019]
　CAI Lizhen,BAI Ruina,ZHANG Lu,et al.Based on the theory of “phlegm blended with blood stasis”,to explore the mechanism and treatment of breast cancer related lymphedema[J].,2023,(4):1420.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.019]
[10]宋铁兵,李康乐,马 强,等.土贝母皂苷甲对乳腺癌细胞MCF-7凋亡的影响[J].陕西中医,2023,(11):1514.[doi:DOI:10.3969/j.issn.1000-7369.2023.11.004]
　SONG Tiebing,LI Kangle,MA Qiang,et al.Effect of Tubeimoside I on apoptosis of breast cancer cell MCF-7[J].,2023,(4):1514.[doi:DOI:10.3969/j.issn.1000-7369.2023.11.004]

备注/Memo

备注/Memo:
[基金项目]河北省中医药管理局科研计划项目(2025019)
更新日期/Last Update: 2025-04-08